Eledon Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Eledon Pharmaceuticals' 2025 annual report details promising clinical trial results for tegoprubart in kidney and islet cell transplantation, alongside ongoing financial losses and the need for additional capital.
NASDAQ
Eledon Pharmaceuticals amends its 2024 Annual Report to restate prior financial statements due to accounting errors, while highlighting progress in its kidney transplantation and islet cell programs and ongoing capital raises.
NASDAQ
Eledon Pharmaceuticals' 2024 10-K filing emphasizes kidney transplantation program advancements and ongoing clinical trials while navigating financial losses and future funding needs.
NASDAQ
Eledon Pharmaceuticals has restated its financial statements for fiscal year 2023 and several interim periods due to an accounting error related to the classification of certain warrants, also identifying a material weakness in internal controls.
NASDAQ
10-K/A: Eledon Pharmaceuticals Files Amendment to 2023 Annual Report, Providing Additional Disclosures
Eledon Pharmaceuticals has filed an amendment to its 2023 annual report to include required information not available at the time of the original filing.
NASDAQ
Eledon Pharmaceuticals' 10-K filing highlights a strategic shift towards kidney transplant programs while facing substantial doubt about its ability to continue as a going concern.